Oral abexinostat for relapsed lymphoma after two prior treatments
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests how well and how safely an oral medicine called abexinostat works for people with diffuse large B-cell lymphoma that has come back or did not respond to the last treatment. It may help by shrinking lymphoma and controlling the disease using a medication taken by mouth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed diffuse large B-cell lymphoma (DLBCL) from a biopsy (histology).
- You have received exactly up to two prior standard treatment plans for DLBCL, including an anti-CD20 antibody plus chemotherapy or other cancer medicines.
- Your lymphoma either did not respond to the last treatment or grew/spread after the last treatment.
- You have at least one measurable lymphoma spot seen on scans (lymph node or tissue outside a node).
- You can do daily activities at a level that fits ECOG 0 to 2 (your study team will assess this).
- Your blood, liver, and kidney tests meet the study’s required ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, glofitamab and selinexor, for patients with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two previous treatments. The goal is to see if this combination can help control the cancer.
This study tests whether taking two pills—zanubrutinib and lenalidomide—after finishing chemotherapy can help keep your DLBCL from coming back. It’s for patients who are already in complete remission after treatment.
This Phase 1 study tests whether an oral medicine called LP-168 can be given safely and possibly work against lymphoma that has come back or is not responding to standard treatment. It’s mainly looking for safety, but your results could help determine whether the drug should be studied further.
This trial tests a new combination of drugs (Pola-ZR2P) for people with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) who have not had chemotherapy yet. It aims to see if this treatment is safe and effective.
This Phase 1/2 study tests AVM0703 in people ages 12+ with certain lymphoid cancers that have returned or not responded to treatment. It may help shrink the cancer or control it when other treatments have failed or are not possible.
This trial tests a combination of targeted drugs and chemotherapy for patients whose large B-cell lymphoma has returned or not improved after first treatment. The goal is to see if this mix works better than standard options.
Hear when a new Diffuse Large B-cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.